TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04253483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: Undergo SABR
Study: NCT03850496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revitive IX Neuromuscular Stimulation Device
Description: Neuromuscular stimulation footplate device with a pre-programmed 30 minute varying electrical stimulation sequence.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revitive IX Neuromuscular Stimulation Device
Description: Neuromuscular stimulation footplate device with a pre-programmed 30 minute varying electrical stimulation sequence.
Study: NCT00676364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% lidocaine topical anesthetic cream
Description: A dollop of 4% lidocaine cream was applied under occlusive dressing for 15 mins prior to venipuncture

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: A dollop of matching placebo cream was applied under occlusive dressing for 15 mins prior to venipuncture
Study: NCT01476878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frameless Stereotactic Radiosurgery with radiation mask
Description: Linac-based radiosurgery using a thermoplastic mask (single treatment)
Study: NCT02169375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain computer Interface Mu (SMR) rhythm
Description: Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 10 sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain computer Interface Mu (SMR) rhythm
Description: Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 10 sessions.
Study: NCT00785655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermacyd PH_DETINLYN (Lactic Acid)
Study: NCT04321226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond Laser guided Arcuate Keratotomy
Description: Astigmatism will be reduced in cataract surgery using a low energy Femtosecond Laser device
Study: NCT03163498

Intervention type: OTHER
Intervention: No intervantion. It´s a Cross-Sectional Study
Description: No intervential

Intervention type: OTHER
Intervention: No intervantion. It´s a Cross-Sectional Study
Description: No intervential
Study: NCT02203227

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioTurmin (Curcuma longa rhizomes extract)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioTurmin-WD (Water dispersible curcuminoids)
Study: NCT01832116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-MMOT0530A
Description: Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
Study: NCT02472964

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab 8mg/kg Iv over 90 minutes x 1 then Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MYL- 1401O
Description: MYL-1401O 8mg/kg Iv over 90 minutes x 1 then HERMyl 1401O Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80mg/m2 IV over 60 minutes weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80mg/m2 IV over 60 minutes weekly.
Study: NCT02203227

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MaQxan
Study: NCT02504827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime/avibactam
Description: Ceftazidime/avibactam 2.5gm iv q8h for 3 doses
Study: NCT02586038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Study: NCT03731819

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Abbreviated PB MRI
Description: Abbreviated PB MRI which targets table time of 10 minutes. For MRI acquisition, standard dose of commercially available MR contrast agent (Gadovist, Bayer, Germany) is used on weight-based dosing (0.1mmol/kg).
Study: NCT04549090

Intervention type: DRUG
Intervention: QL (quadratus lumborum) block administration
Description: Fo the QL block group, they will be receiving bilateral QL block. A total of 40ml of 0.25% bupivacaine (Marcaine) and 10ml of liposomal bupivacaine (Exparel) will be administered
Study: NCT01743560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were to be treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
Study: NCT01686126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Description: Intrauterine device
Study: NCT02472964

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 IV over 60 minutes on day 1 of a 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 IV over 60 minutes on day 1 of a 3 week cycle
Study: NCT01215292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 300 mcg/kg on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acyline
Description: 300 mcg/kg on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 300 mcg/kg on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 300 mcg/kg on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 300 mcg/kg on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: 5 gm of 1% T Gel applied transdermally for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone gel
Description: 5 gm of 1% T Gel applied transdermally for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: 5 gm of 1% T Gel applied transdermally for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: 5 gm of 1% T Gel applied transdermally for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: 5 gm of 1% T Gel applied transdermally for 10 days
Study: NCT01686126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Description: Intrauterine device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Description: Intrauterine device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: oral medication
Study: NCT01059422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir; Abacavir/Lamivudine
Description: Raltegravir: 400 mg twice daily Abacavir/Lamivudine fixed-dose combination: 600mg/300mg once daily
Study: NCT01215292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole 400
Description: 400 mg PO daily, Days 3-10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole 800
Description: 800 mg PO daily, Day 3-10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: 2.5 mg PO daily, Day 3-10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg PO daily, Day 3-10

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ketoconazole
Description: placebo to mimic ketoconazole
Study: NCT02154763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study: NCT03869398

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tums
Description: start their calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: start their calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
Study: NCT04534374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Barbell back squat, press, and deadlift for three sets of five repetitions with the weight closest to 75% of their estimated 1 repetition max. The participants were instructed to execute the movement with moderate speed (2s eccentric, 2s concentric, no pause in between). The rest period between sets and exercise movements was two to three minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercise (sham exercise)
Description: Participants completed a passive stretching exercise session for a similar duration of time as the resistance exercise (≈ 30 min) as sham intervention, which included 15-20 stretching movements twice, holding each for 30 seconds as recommended by ACSM.
Study: NCT02660827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin Pump
Description: Closed Loop Algorithm
Study: NCT03102723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: 1. Cangrelor treatment: IV Cangrelor as a single IV bolus (30 μg/kg) followed by an infusion (4 μg/kg/min) of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI. This dosing regimen is identical to that used in the CHAMPION trials.~   Or~2. Placebo control: IV normal saline as a single IV bolus followed by an infusion of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cangrelor
Description: 1. Cangrelor treatment: IV Cangrelor as a single IV bolus (30 μg/kg) followed by an infusion (4 μg/kg/min) of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI. This dosing regimen is identical to that used in the CHAMPION trials.~   Or~2. Placebo control: IV normal saline as a single IV bolus followed by an infusion of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI.
Study: NCT03372200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981
Description: Oral daily dosing for 14 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat
Description: Oral daily dosing for 14 weeks
Study: NCT01744652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Arm A Crizotinib dose: 250 mg by mouth twice a day in a 28 day cycle. Crizotinib Expansion dose: 250 mg by mouth twice a day in a 28 day cycle.~Arm B Crizotinib starting dose: 250 mg by mouth every other day in a 28 day cycle. Crizotinib Expansion Dose: MTD from dose escalation group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Arm A Crizotinib dose: 250 mg by mouth twice a day in a 28 day cycle. Crizotinib Expansion dose: 250 mg by mouth twice a day in a 28 day cycle.~Arm B Crizotinib starting dose: 250 mg by mouth every other day in a 28 day cycle. Crizotinib Expansion Dose: MTD from dose escalation group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Arm A Dasatinib starting dose: 50 mg by mouth daily in a 28 day cycle. Arm A Dasatinib Expansion Dose: MTD from dose escalation group.~Arm B Dasatinib dose: 140 mg by mouth daily in a 28 day cycle. Arm B Dasatinib Expansion Dose: 140 mg by mouth daily in a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Arm A Dasatinib starting dose: 50 mg by mouth daily in a 28 day cycle. Arm A Dasatinib Expansion Dose: MTD from dose escalation group.~Arm B Dasatinib dose: 140 mg by mouth daily in a 28 day cycle. Arm B Dasatinib Expansion Dose: 140 mg by mouth daily in a 28 day cycle.
Study: NCT03154008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy will follow the Adolescent Coping with Depression Course (CWD; Clarke et al., 1999), an established 16-session group treatment protocol, and consist of behavioral activation, relaxation skills, cognitive therapy, social skills, problem solving, and relapse prevention.
Study: NCT01522417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short Tirofiban
Description: 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eptifibatide
Description: 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long Tirofiban
Description: 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post-PCI.
Study: NCT00450411

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 125-Iodine
Description: Brachytherapy to the prostate via 125-iodine (I-125) seeds with a planned dose of 140 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 103-palladium
Description: Brachytherapy to the prostate via 103-palladium (Pd-103) seeds with a planned dose of 120 Gy
Study: NCT04656834

Intervention type: PROCEDURE
Intervention: hand incision closure using monocryl sutures and skin glue
Description: At the end of surgery, the investigator will close the incision using monocryl sutures and skin glue

Intervention type: PROCEDURE
Intervention: hand incision closure using simple nylon sutures
Description: At the end of surgery, the investigator will close the incision using simple nylon sutures
Study: NCT03105310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa
Description: Pegylated interferon alfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa
Description: Pegylated interferon alfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe
Study: NCT04999813

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Comprehensive intensive intervention
Description: * Health education ② Medication guidance: antihypertensive therapy, hypoglycemic therapy, lipid-lowering therapy~  * Diet guidance: A healthy diet requires low-salt, low-oil, more fruits and vegetables, more cellulose, appropriate amount of protein, restricted fat and cholesterol foods, etc. Quit smoking, drink less alcohol, and limit alcohol intake.~    * Exercise guidance: Do aerobic exercises of medium and low intensity at least 5 times a week, and exercise for at least 30 minutes each time.~      * Weight loss guidance.
Study: NCT01417026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Oxytocin (Trade name: Syntocinon)
Description: This is a double-blind placebo-controlled trial of intranasal oxytocin in children and adolescents with ASD. Subjects will be randomized to 24 IU intranasal oxytocin or placebo for a 5 day period with concomitant game play of computer games, which are designed to enhance face perception skills. Measures of social function and cognition will be administered before and after the intervention period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Oxytocin (Trade name: Syntocinon)
Description: This is a double-blind placebo-controlled trial of intranasal oxytocin in children and adolescents with ASD. Subjects will be randomized to 24 IU intranasal oxytocin or placebo for a 5 day period with concomitant game play of computer games, which are designed to enhance face perception skills. Measures of social function and cognition will be administered before and after the intervention period.
Study: NCT03686046

Intervention type: OTHER
Intervention: Exploratory use
Description: Participants will be accompanied by a researcher while wearing the open-source speech processing platform as a hearing aid - adjusted to their needs using a widely accepted Fitting prescription. Using a hand-held controller, they will readjust to their liking as the acoustic conditions change. After returning to the laboratory, they will complete speech perception tests using under their self-selected amplification conditions and respond to a structured interview dealing with perceived performance of the device and its acceptability as a hearing aid during possible field studies.
Study: NCT01037348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab 0.5mg
Study: NCT01751828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Study: NCT02808364

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized cellular vaccine
Description: Patients with recurrent glioblastoma will undergo tumor resection and receive tumor antigen pulsed cellular vaccines.
Study: NCT03519854

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl administered as a fast IV bolus dose (within 30 seconds).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl administered as a fast IV bolus dose (within 30 seconds).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl administered as a fast IV bolus dose (within 30 seconds).
Study: NCT04135469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral for tax preparation services
Description: Printed materials will be provided with contact information for tax preparation services at BMC and other sites in the city.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral for tax preparation services
Description: Printed materials will be provided with contact information for tax preparation services at BMC and other sites in the city.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Navigator assisted tax preparation services at BMC
Description: A study navigator will assist the participant in accessing the BMC located tax preparation services.
Study: NCT00416182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmozyme (dornase alfa)
Description: 2.5 mg/2.5 mL of Pulmozyme (dornase alfa) delivered via Sinustar nasal nebulizer device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2.5 mL of placebo delivered via Sinustar nebulizer device
Study: NCT03352791

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DSM-H Hospice Edition performance improvement program
Description: Patients in the performance improvement group will receive care from a care team who has received the DSM-H Hospice Edition performance improvement program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: control will receive usual care from a care team who has not received the performance improvement program.
Study: NCT01567384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906 and Pemetrexed
Description: Pemetrexed will be administered intravenously on day 1 of cycle 1 at a dose of 500 mg/m2 as a 10-minute infusion. Subsequent doses will be defined by tolerability.~OSI-906 will be administered orally twice daily (12 hours apart) at approximately the same times each day on a continuous schedule, beginning on Day 0 of cycle 1.
Study: NCT03832595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHR-based PHM
Description: An EHR in-basket message will be sent to the patient's PCP which identifies the patient's high-risk CKD status and indicates that the patient will receive:~1. Nephrologist led electronic consultation: review of the patient's EHR with recommendations sent to the PCP every \~6 months,~2. Medication therapy management: PharmD led telephonic medication therapy management with the patient every \~6 months,~3. and Nurse led CKD patient education, every \~6-12 months~unless the PCP opts the patient out of the interventions (by responding to the EHR in-basket message and providing an opt-out reason or requesting an office consultation with nephrology).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients in the usual care arm will continue to receive CKD care guided by their PCPs as per usual care practices (i.e., specialty consultation, pharmacotherapy, nurse education, etc. may be ordered by the PCP according to their usual practice).
Study: NCT00803452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: Oral doxycycline 100mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: topical 1% azithromycin daily to eye
Study: NCT01818479

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stem cell transplant
Description: Open label, dose finding trial with two treatment regimens, Busulfan and Total Body Irradiation (TBI) with four dose escalation cohorts, to assess the efficacy of Treg/Tcon addback to partially matched related donor stem cells.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplant
Study: NCT02115880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention programme
Description: Based on a group- and family-based cognitive behavioural manual developed by Bruce Compas and colleagues in the USA, and adapted for a German sample. The programme is for parents and children and consists of 8 weekly sessions and 4 monthly booster sessions.